Kerri Fitzgerald

DocwireNews

Intravitreal injection is the most common surgical ophthalmologic procedure worldwide, and in the United States, most intravitreal injections are performed on the same day as an office examination. However, federal agencies and insurance payers suggest that same-day examination charges (as noted with modifier-25) are overutilized.&nbsp;In a study, researchers found that modifier-25 same-day examinations during anti-vascular endothelial growth factor (VEGF) therapy for wet age-related macular degeneration (AMD) reduced treatment and travel costs and improved screening of the fellow eye, resulting in &ldquo;robust cost savings and quality-adjusted life-years (QALY) benefit,&rdquo; according to the authors. The results of the study were published as part of the American Society of Retina Specialists 2020 Virtual Annual Meeting.&nbsp;Researchers modeled different anti-VEGF treatment scenarios for wet AMD. Treatment parameters for intravitreal injections, office examinations, and optical coherence tomography (OCT) testing payments were estimated using U.S. population statistics, published literature, and Centers for Medicare &amp; Medicaid Services provider utilization data.&nbsp;Costs and benefits were compared for three established treatment scenarios: (1) continuous anti-VEGF therapy (10.1 injections; 1.9 office examinations per year), (2) office-based treat and extend (T&amp;E) anti-VEGF therapy (5.8 injections; 5.8 same-day office visits per year), and (3)&nbsp;anti-VEGF therapy in an injection clinic (8.6 injections; 4.7 same-day office visits per year).&nbsp;They also assessed three types of costs: (1) direct cost of care (exams, testing, injections, drugs), (2) cost of patient and chaperone time, and (3) cost of lost vision in the fellow eye from delayed diagnosis and treatment.Although office examinations and OCT costs were higher for T&amp;E ($858) and injection clinic ($497) protocols versus continuous treatment ($280), the model predicted reduced yearly treatment costs for T&amp;E ($6,858) and injection clinic ($10,131) compared with continuous treatment ($11,860). This was due to decreased pharmaceutical expenses related to less frequent treatment.Travel and chaperone costs were reduced for T&amp;E ($536) and injection clinic ($672) versus continuous treatment ($942).&nbsp;For the U.S. population, there was an estimated annual cost savings of $7.2 billion for the T&amp;E protocol and $2.7 billion for the injection clinic compared with continuous therapy.&nbsp;Early detection of wet AMD in the fellow eye during same-day office examinations allowed for a 2.1 and 1.8 QALY benefit per patient in the T&amp;E and injection clinic cohorts, respectively, compared with the continuous treatment arm, with a favorable $5,402 and $2,891 cost per QALY, respectively.&ldquo;We conclude that same-day examinations are a valuable component of anti-VEGF therapy in the treatment of wet AMD because they allow personalization of the treatment regimen, reduce travel burden, and save on treatment costs,&rdquo; the researchers concluded.Leder HA, Mason RWH, Lee GD, et al. Modifier-25 Examinations Reduce Travel Burden, Decrease Treatment Cost, and Improve QALY for Exudative Age-Related Macular Degeneration Patients. Presented during the ASRS 2020 Virtual Annual Meeting, July 24-26, 2020.

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Same-Day Exam and Anti-VEGF Treatment for Wet AMD Reduces Treatment and Travel Costs

ASRS 2020

Intravitreal injection is the most common surgical ophthalmologic procedure worldwide, and in the United States, most intravitreal injections are performed on the same day as ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe